These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33564172)

  • 21. Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
    Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
    PLoS One; 2020; 15(1):e0228072. PubMed ID: 31961902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy.
    Bello L; Pegoraro E
    Acta Myol; 2016 Dec; 35(3):122-127. PubMed ID: 28484312
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-viral gene therapy for Duchenne muscular dystrophy: progress and challenges.
    Rando TA
    Biochim Biophys Acta; 2007 Feb; 1772(2):263-71. PubMed ID: 17005381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene editing and modulation for Duchenne muscular dystrophy.
    Stephenson AA; Flanigan KM
    Prog Mol Biol Transl Sci; 2021; 182():225-255. PubMed ID: 34175043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Mutation-specific treatments for Duchenne muscular dystrophy].
    Matsuo M; Takeshima Y
    Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Causes of clinical variability in Duchenne and Becker muscular dystrophies and implications for exon skipping therapies.
    Hoffman EP
    Acta Myol; 2020 Dec; 39(4):179-186. PubMed ID: 33458572
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Common therapeutic advances for Duchenne muscular dystrophy (DMD).
    Salmaninejad A; Jafari Abarghan Y; Bozorg Qomi S; Bayat H; Yousefi M; Azhdari S; Talebi S; Mojarrad M
    Int J Neurosci; 2021 Apr; 131(4):370-389. PubMed ID: 32241218
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.
    Cai A; Kong X
    Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic developments for Duchenne muscular dystrophy.
    Verhaart IEC; Aartsma-Rus A
    Nat Rev Neurol; 2019 Jul; 15(7):373-386. PubMed ID: 31147635
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach.
    Patterson G; Conner H; Groneman M; Blavo C; Parmar MS
    Eur J Pharmacol; 2023 May; 947():175675. PubMed ID: 36963652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. From diagnosis to therapy in Duchenne muscular dystrophy.
    Babbs A; Chatzopoulou M; Edwards B; Squire SE; Wilkinson IVL; Wynne GM; Russell AJ; Davies KE
    Biochem Soc Trans; 2020 Jun; 48(3):813-821. PubMed ID: 32597486
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study.
    Kinali M; Arechavala-Gomeza V; Feng L; Cirak S; Hunt D; Adkin C; Guglieri M; Ashton E; Abbs S; Nihoyannopoulos P; Garralda ME; Rutherford M; McCulley C; Popplewell L; Graham IR; Dickson G; Wood MJ; Wells DJ; Wilton SD; Kole R; Straub V; Bushby K; Sewry C; Morgan JE; Muntoni F
    Lancet Neurol; 2009 Oct; 8(10):918-28. PubMed ID: 19713152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
    Hwang J; Yokota T
    Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical approaches in the treatment of Duchenne muscular dystrophy (DMD) using oligonucleotides.
    Bertoni C
    Front Biosci; 2008 Jan; 13():517-27. PubMed ID: 17981565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR-Generated Animal Models of Duchenne Muscular Dystrophy.
    Lim KRQ; Nguyen Q; Dzierlega K; Huang Y; Yokota T
    Genes (Basel); 2020 Mar; 11(3):. PubMed ID: 32213923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9.
    Koo T; Lu-Nguyen NB; Malerba A; Kim E; Kim D; Cappellari O; Cho HY; Dickson G; Popplewell L; Kim JS
    Mol Ther; 2018 Jun; 26(6):1529-1538. PubMed ID: 29730196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exon skipping and Duchenne muscular dystrophy: hope, hype and how feasible?
    Wilton SD; Fletcher S
    Neurol India; 2008; 56(3):254-62. PubMed ID: 18974551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel rabbit model of Duchenne muscular dystrophy generated by CRISPR/Cas9.
    Sui T; Lau YS; Liu D; Liu T; Xu L; Gao Y; Lai L; Li Z; Han R
    Dis Model Mech; 2018 Jun; 11(6):. PubMed ID: 29871865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.